Jumar Bioincubator, Australia’s newest biotech incubator, has officially opened its doors and announced the first 16 creative early-stage ventures to move into its much-anticipated Melbourne location.
Jumar’s cutting-edge facilities, infrastructure, and support establish a world-class hub for biotech innovation translation, research commercialization, and talent development, accelerating the progression of discoveries to real-world patient therapies.
It aims to build “Australia’s next CSL” by leveraging the talent and capabilities of the local biotech research community to support the next homegrown global success story, as well as to create a critical mass of entrepreneurially skilled scientists capable of running successful biotech companies.
The 16 unique early-stage startups include Tessara Therapeutics (producing “mini brains” in test tubes through 3D neural micro-tissues), ovulation bio-sensing startup Symex Labs; Denteric (developing a therapeutic vaccine for the one billion people worldwide suffering from periodontal gum disease); Australian Genome Research Facility (AGRF); Arovella Therapeutics (developing an invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat cancer); Centre for Biomedical Excellence (CBE); H3D’s objective is to make custom-fit medical devices available to everyday people; Immunosis (creating a pioneering diagnostic platform with the goal of quickly identifying immunological dysfunctions); Inosi Therapeutics (developing therapeutics for fibrosis); Novoroo (creating innovative pharmaceutical techniques to address neurological impairment); Nutromics’ breakthrough technique is a patch made up of DNA-based sensors; Pacalis Therapeutics uses intellectual property created at Monash University to achieve advances in medication discovery.
Qankorey is investigating essential technologies in the prevention, screening, diagnosis, and treatment of Alzheimer’s disease. RAGE Biotech develops innovative medicines targeting the Receptor for Advanced Glycation End-products (RAGE) for patients with difficult-to-treat inflammatory illnesses. Titan is a Contract Research Organisation (CRO), and 23Strands has demonstrated the ability to deliver genome-wide DNA sequencing data.